{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T10:00:43Z","timestamp":1785405643204,"version":"3.56.0"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Numerous factors may influence the optimal rollout of new gonococcal antibiotics. We compared 8 rollout strategies using a gonorrhea transmission model and ranked strategies by the number of gonococcal infections and clinically useful antibiotic lifespan. Rankings were most sensitive to the starting ceftriaxone resistance prevalence and screening frequency.<\/jats:p>","DOI":"10.1093\/ofid\/ofag447","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:40:53Z","timestamp":1784288453000},"source":"Crossref","is-referenced-by-count":0,"title":["Local Prevalence of Ceftriaxone Resistance Informs Optimal Deployment of New Gonorrhea Treatments"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3468-2014","authenticated-orcid":false,"given":"Kirstin I","family":"Oliveira Roster","sequence":"first","affiliation":[{"name":"Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9292-5670","authenticated-orcid":false,"given":"Minttu M","family":"R\u00f6nn","sequence":"additional","affiliation":[{"name":"Department of Global Health and Population, Harvard T.H. Chan School of Public Health , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva R","family":"Gorenburg","sequence":"additional","affiliation":[{"name":"Program in Human Biology, Stanford University , Stanford, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis K","family":"Partl","sequence":"additional","affiliation":[{"name":"Institute of Medical Virology, University of Zurich , Zurich ,","place":["Switzerland"]},{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich , Zurich ,","place":["Switzerland"]},{"name":"Institute of Social and Preventive Medicine, University of Bern , Bern ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanina","family":"Anderegg","sequence":"additional","affiliation":[{"name":"Institute of Medical Virology, University of Zurich , Zurich ,","place":["Switzerland"]},{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Abel zur Wiesch","sequence":"additional","affiliation":[{"name":"University of Troms\u00f8 - The Arctic University of Norway Department of Pharmacy, , Troms\u00f8 ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Au","sequence":"additional","affiliation":[{"name":"Global Antibiotic Research and Development Partnership , Geneva ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9220-8348","authenticated-orcid":false,"given":"Roger D","family":"Kouyos","sequence":"additional","affiliation":[{"name":"Institute of Medical Virology, University of Zurich , Zurich ,","place":["Switzerland"]},{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando P","family":"Martinez","sequence":"additional","affiliation":[{"name":"Global Antibiotic Research and Development Partnership , Geneva ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4817-8986","authenticated-orcid":false,"given":"Nicola","family":"Low","sequence":"additional","affiliation":[{"name":"Institute of Social and Preventive Medicine, University of Bern , Bern ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5646-1314","authenticated-orcid":false,"given":"Yonatan H","family":"Grad","sequence":"additional","affiliation":[{"name":"Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,18]]},"reference":[{"key":"2026073005165864800_ofag447-B1"},{"key":"2026073005165864800_ofag447-B2","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1093\/jac\/dkac159","article-title":"A systematic review of antimicrobial resistance in Neisseria gonorrhoeae and Mycoplasma genitalium in sub-Saharan Africa","volume":"77","author":"Iwuji","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026073005165864800_ofag447-B3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13756-021-00931-w","article-title":"Surveillance of antimicrobial resistance in low- and middle-income countries: a scattered picture","volume":"10","author":"Iskandar","year":"2021","journal-title":"Antimicrob Resist Infect Control"},{"key":"2026073005165864800_ofag447-B4","volume-title":"WHO guidelines for the treatment of Neisseria gonorrhoeae","author":"World Health Organization","year":"2016"},{"key":"2026073005165864800_ofag447-B5","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1071\/SH18191","article-title":"Providing competent, comprehensive and inclusive sexual health services for men who have sex with men in low- and middle-income countries: a scoping review","volume":"16","author":"Bien-Gund","year":"2019","journal-title":"Sex Health"},{"key":"2026073005165864800_ofag447-B6","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41579-024-01023-3","article-title":"Antimicrobial treatment and resistance in sexually transmitted bacterial infections","volume":"22","author":"Jensen","year":"2024","journal-title":"Nat Rev Microbiol"},{"key":"2026073005165864800_ofag447-B7","doi-asserted-by":"crossref","first-page":"54","DOI":"10.14745\/ccdr.v45i23a02","article-title":"Addressing the rising rates of gonorrhea and drug-resistant gonorrhea: there is no time like the present","volume":"45","author":"Bodie","year":"2019","journal-title":"Can Commun Dis Rep"},{"key":"2026073005165864800_ofag447-B8","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/S0140-6736(25)00628-2","article-title":"Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study","volume":"405","author":"Ross","year":"2025","journal-title":"Lancet"},{"key":"2026073005165864800_ofag447-B9","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0140-6736(25)01953-1","article-title":"Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial","volume":"407","author":"Luckey","year":"2026","journal-title":"Lancet"},{"key":"2026073005165864800_ofag447-B10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s44263-024-00087-w","article-title":"Recommendations for the optimal introduction of novel antibiotics to treat uncomplicated gonorrhoea in the face of increasing antimicrobial resistance: a case study with zoliflodacin","volume":"2","author":"Pascual","year":"2024","journal-title":"BMC Glob Public Health"},{"key":"2026073005165864800_ofag447-B11","author":"Food and Drug Administration"},{"key":"2026073005165864800_ofag447-B12","doi-asserted-by":"crossref","first-page":"e781","DOI":"10.1016\/S2666-5247(23)00145-3","article-title":"Resistance-minimising strategies for introducing a novel antibiotic for gonorrhoea treatment: a mathematical modelling study","volume":"4","author":"Reichert","year":"2023","journal-title":"Lancet Microbe"},{"key":"2026073005165864800_ofag447-B13","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1093\/infdis\/jiaf071","article-title":"High prevalence of ceftriaxone-resistant Neisseria gonorrhoeae in Hanoi, Vietnam, 2023\u20132024","volume":"232","author":"Laumen","year":"2025","journal-title":"J Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag447\/69272115\/ofag447.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/7\/ofag447\/69272115\/ofag447.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/7\/ofag447\/69272115\/ofag447.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:17:06Z","timestamp":1785403026000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag447\/8737049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag447","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,7,1]]},"article-number":"ofag447"}}